Partnering Success

View Immunovaccine's Inc. Partnerships in a larger map

Immunovaccine is pleased to have signed partnership agreements with:

	Atlantic Canada Opportunities Agency (ACOA) for funding and development of improved vaccine formulations UPDATE - March 2011 ACOA awarded Immunovaccine $2.9M under the Atlantic Innovation Fund
	Cel-Sci Corp. to develop a therapeutic vaccine for rheumatoid arthritis. UPDATE: Early results show the combination of CEL-2000, a rheumatoid arthritis (RA) vaccine antigen, and DepoVax lessened the symptoms and slowed the progression of RA in the animal model with a single dose. Further research is underway to optimize the CEL-2000-DepoVax vaccine combination for possible testing in Phase I clinical trials.
	CIMAB, S.A. of Cuba, to enhance an EGF peptide cancer antigen UPDATE: At discovery stage of optimizing the vaccine formulation.
	Dana-Farber Cancer Institute to develop vaccines using HIV indications UPDATE: Preliminary research discussions underway.
	Defence Research & Development Canada to develop vaccines against anthrax and melioidosis UPDATE: Early results show that the DepoVax platform can generate rapid single dose protection. The new vaccine formulation raises antibody levels 10 times higher, on average, than a comparable alum-adjuvanted anthrax vaccine. The Anthrax-DepoVax formulation also comes in a dry format that is easily reconstituted, making it well suited for an effective anti-anthrax vaccine. Preliminary research on meliodosis is underway.
	IRX Therapeutics, a NY-based company, to develop new combination cancer immunotherapies UPDATE: Current research is evaluating the combination of IRX’s primary cell-derived biologic, IRX-2, with DepoVax-based therapeutic cancer vaccines with the goal of demonstrating a superior anti-tumor immune response.
	La Jolla Institute for Allergy & Immunology (LIAI) to apply DepoVax™ vaccine delivery system to develop vaccines against seasonal and pandemic influenza. UPDATE: Novel epitope-based vaccines in the DepoVax formulation are being evaluated in proof-of-concepts models for influenza and arena virus.
	National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), to formulate potential vaccines for HIV and malaria. The NIH is the largest health research government agency in the US. UPDATE: Several pre-clinical studies are underway to evaluate how each specified protein is to be formulated in DepoVax to induce stronger immune responses.
	National Cancer Institute (NCI) to enhance the delivery of their cancer vaccine antigens UPDATE: Research collaboration is outling the design and characterization of select vaccines for research discovery.
	National Research Council (NRC) Canada to develop carbohydrate-based vaccines targeting meningitis and cancer UPDATE: Researchers are presently optimizing the new vaccine formulation for discovery.
	NRC /Institute of Biodiagnostics to develop novel methods to detect DepoVax™ effect on tumours UPDATE: Continuing research to develop iron oxide labels for the vaccine and immune cells that respond to the vaccine to examine the vaccine's action in the body.
	OncoTherapy Science, of Japan, to enhance peptide cancer antigens UPDATE: Preclinical studies underway to evaluate how the DepoVax platform enhances these novel cancer peptides to function as unique targets for anti-angiogenic therapy.
	Oncothyreon Inc., Seattle, WA, to develop a MUC 1 based therapeutic cancer vaccine UPDATE: Discovery stage to optimize the vaccine formulation and identify appropriate disease model.
	Scancell Ltd., a UK-based company, to advance novel peptide vaccines UPDATE: Discovery stage compiling information on both technologies.
	Vaxil BioTherapeutics, an Israel-based company, to enhance cancer antigens UPDATE: Discovery stage compiling information and testing novel vaccine formulations.